Those selected for the SBC work with local mentors, giving students hands-on research experience in a professional lab setting.
[5] In 2014, Sanofi Pasteur stopped producing its effective Fav-Afrique antivenom because competition from cheaper though less powerful competitors made it unprofitable.
By April 2012 the FDA had found dozens of documented problems with sterility at the plant including mold, nesting birds and rusted electrical conduits, as well as numerous procedural safety issues and violations.
[10] The Philippine Department of Health began in 2016 a programme in three regions to vaccinate schoolchildren against dengue fever, using Dengvaxia supplied by Sanofi Pasteur.
[13] In July 2020, Sanofi Pasteur announced that it would begin phase three testing of a COVID-19 vaccine in several countries, including Mexico, and that the cost would be US $7 to $10 per dose.